The pharmaceutical market greece


Published on

Medical devices: EUR670mn (US$931mn) in 2011 to EU607mn (US$771mn) in 2012; -9.3% in local currency terms and -17.1% in US dollar terms. Forecast unchanged from Q3 12.

Published in: Business, News & Politics
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

The pharmaceutical market greece

  1. 1. The Pharmaceutical Market: Greece THE PHARMACEUTICAL MARKET: GREECE - REVIEW The immediate threat of a Greek default and eurozone exit was reduced as the outcome of the legislative elections in June had a much more benign outcome than many feared. A n exit would have - and could still be - disastrous for drugmakers operating in the market. But even Greece staying in the monetary union means the government must continue with its austerity programme. While we continue to hold to our view that Germany and the rest of the EU may reduce the focus on austerity and introduce some pro-growth strategies, these are unlikely to generate any upside for the pharmaceutical industry and structural reforms within Greece will be maintained. T he government remains committed to huge cuts in its public drug expenditure for 2012, with a painful claw-back tax in operation and no extra resources available to pay-back existing debts. Headline Expenditure Projections Pharmaceuticals: EUR6.72bn (US$9.35bn) in 2011 to EUR5.92bn (US$7.52bn) in 2012; -12.0% in local currency terms and -19.6% in US dollar terms. Forecast broadly maintained from Q3 12. Healthcare: EUR21.80bn (US$30.31bn) in 2011 to EUR20.34bn (US$25.83bn) in 2012; -6.7% in local currency terms and -14.8% in US dollar terms. Forecast broadly stable from Q3 12. Medical devices: EUR670mn (US$931mn) in 2011 to EU607mn (US$771mn) in 2012; -9.3% in local currency terms and -17.1% in US dollar terms. Forecast unchanged from Q3 12. Risk/RewardRating In our latest RRRs, we have revised down our assessment of the Greek market, with a downgrade to the industry risk score as a result of broadly unfavourable operating conditions worsening, specifically re-payment terms, which we have criticised previously, and our assessment of whether innovative drugmakers would want to launch new products on the market. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. table Of Contents bmi Industry View 7 swot 10 political 12 economic 13 business Environment 14 industry Forecast 15 pharmaceutical Market Forecast 15 table: Greece Pharmaceutical Sales, Historical Data And Forecasts 18 healthcare Market Forecast 19 table: Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 20 table: Healthcare Governmental Indicators, 2009-2017 20 table: Healthcare Private Indicators, 2009-2017 21 economic Analysis 21 table: Economic Activity 25 prescription Drugs Market Forecast 26 table: Prescription Drug Sales Indicators, 2009-2017 27 patented Drugs Market Forecast 28 table: Patented Drug Sales, 2009-2017 29 The Pharmaceutical Market: Greece
  2. 2. generic Drugs Market Forecast 30 table: Generic Drug Sales, 2009-2017 31 otc Medicine Market Forecast 32 table: Otc Medicine Sales, 2009-2017 33 table: Otc Medicine Sales Breakdown, 2007-2010 33 pharmaceutical Trade Forecast 34 table: Pharmaceutical Trade Forecast, 2009-2017 35 key Risks To Bmi's Forecast Scenario 36 industry Risk Reward Ratings 37 table: Central And Eastern Europe Pharmaceutical Risk/reward Ratings, Q213 37 rewards 38 risks 39 market Overview 41 industry Trends And Developments 44 epidemiology 44 healthcare Sector 45 infrastructure 49 table: Inpatient Facilities And Beds By Speciality, 2008 49 table: Outpatient Facilities And Beds By Region, 2008 50 drug Retailing 51 table: Pharmacies By Region, 2007-2009 51 regulatory Development 52 regulatory Regime 52 intellectual Property Regime 53 pricing Regime 53 table: Quarterly Total Sales Volume Per Medicinal Product (additional To 9% Of The Current Decision Rebate Amount) 55 reimbursement Regime 58 competitive Landscape 61 The Pharmaceutical Market: Greece
  3. 3. company Profile 63 abbott Laboratories 63 alapis Pharma 65 elpen 68 genesis Pharma 70 glaxosmithkline 72 kleva 74 lavipharm 76 merck Sharpe & Dohme 78 novartis 80 sanofi 82 pfizer 84 pharmathen 86 vianex 88 demographic Forecast 90 table: Greece's Population By Age Group, 1990-2020 ('000) 91 table: Greece's Population By Age Group, 1990-2020 (% Of Total) 92 table: Greece's Key Population Ratios, 1990-2020 93 table: Greece's Rural And Urban Population, 1990-2020 93 methodology 94 methodology 94 risk/reward Ratings Methodology 94 ratings Overview 95 table: Pharmaceutical Business Environment Indicators 95 weighting 96 table: Weighting Of Components 96 sources 96 The Pharmaceutical Market: Greece
  4. 4. glossary 97 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: The Pharmaceutical Market: Greece